Efficacy of Rituximab and Inebilizumab in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Real-World Study

美罗华 髓鞘少突胶质细胞糖蛋白 医学 疾病 抗体 髓鞘相关糖蛋白 免疫学 髓鞘 皮肤病科 病理 内科学 中枢神经系统 实验性自身免疫性脑脊髓炎
作者
Philippe‐Antoine Bilodeau,Takahisa Mikami,Anastasia Vishnevetsky,Monique Anderson,Mattia Wruble,Rebecca L. Gillani,Gabriela Romanow,Rebecca Salky,Melanie Delgado,Michael Levy
出处
期刊:Neurology [Lippincott Williams & Wilkins]
卷期号:103 (7_Supplement_1) 被引量:2
标识
DOI:10.1212/01.wnl.0001051732.71906.95
摘要

Objective To determine relapse-free survival probabilities in MOGAD patients on rituximab, compare these to inebilizumab, and determine predictors of rituximab failure Background Rituximab efficacy in myelin oligodendrocyte glycoprotein Antibody Disease (MOGAD) relapse prevention is controversial, with some groups finding moderate success, while our group has found significantly lower efficacy compared to IVIG. Design/Methods We performed a retrospective analysis of MOGAD patients at Mass General Brigham. We conducted a Kaplan-Meier survival analysis for patients treated with rituximab and extracted relapse freedom probabilities at 6, 12, 18, 24, and 30 months. We determined survival probabilities from the Kaplan-Meier curves of MOG-IgG positive patients in the inebilizumab NMO-mentum trial. We then performed a multivariate Cox proportional hazards analysis to determine predictors of rituximab failure. Results 201 patients with MOGAD were identified. 56 patients received at least one course of rituximab. Mean age of disease onset was 39.6 years (SD 16.0), and 58.9% were female. 62.5% of patients had never received any prior treatment before starting rituximab. Relapse-free survival probabilities were 60.7% at 6 months, 51.1% at 12 months, and 41.8% at 18 months. The N-MOmentum trial for inebilizumab included 7 MOG IgG positive patients. Only 1/7 patients had a relapse at the end of the open label extension. Using the 18-month relapse probabilities from rituximab-treated MOGAD patients, the probability of observing 1 relapse over this time course is 4.5%, assuming similar efficacy. In a multivariate Cox model, patients who never smoked had a lower risk of failure (HR 0.06, 95% CI 0.00012-0.31), while a one-unit increase in BMI was associated with a higher risk of failure (HR 1.36, 95% CI 1.03-1.79). Conclusions The rituximab failure rate is significant in our cohort, in contrast to the relative efficacy of inebilizumab. This may reflect differences in accessing pathogenic B cells or inebilizumab-mediated depletion of plasmablasts and short-lived plasma cells.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
1秒前
2秒前
犹豫颖完成签到,获得积分10
2秒前
Hello的应助被qin202569采纳,获得10
2秒前
北风北风完成签到,获得积分10
2秒前
2秒前
2秒前
3秒前
顾矜的应助被清歌采纳,获得10
3秒前
3秒前
3秒前
4秒前
李知恩发布了新的文献求助20
4秒前
4秒前
FF发布了新的文献求助10
4秒前
温暖砖头发布了新的文献求助10
4秒前
何大爷发布了新的文献求助10
5秒前
北风北风发布了新的文献求助20
5秒前
5秒前
369ninja的应助被如意的醉蓝采纳,获得10
6秒前
flymove完成签到,获得积分10
6秒前
HaoHao04完成签到 ,获得积分10
7秒前
科研通AI6.2的应助被corleeang采纳,获得10
7秒前
制作人完成签到,获得积分10
7秒前
大意的茈发布了新的文献求助10
8秒前
ililiiris发布了新的文献求助10
8秒前
8秒前
8秒前
打桩机完成签到 ,获得积分10
8秒前
坚强孤容发布了新的文献求助10
8秒前
愤怒的项链完成签到 ,获得积分10
8秒前
9秒前
哈哈哈哈完成签到,获得积分10
9秒前
9秒前
危机的盼晴完成签到,获得积分10
9秒前
JanaL发布了新的文献求助10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124